<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS199779</article-id><article-id pub-id-type="doi">10.1101/2024.10.30.621041</article-id><article-id pub-id-type="archive">PPR932562</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Electrostatic interactions define nacubactam potency against OXA-48-like β-lactamases</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hoff</surname><given-names>Joseph F.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Goudar</surname><given-names>Kirsty E.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Beer</surname><given-names>Michael</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hinchliffe</surname><given-names>Philip</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Shaw</surname><given-names>John M.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Tooke</surname><given-names>Catherine L.</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Takebayashi</surname><given-names>Yuiko</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mulholland</surname><given-names>Adrian J.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schofield</surname><given-names>Christopher J.</given-names></name><xref ref-type="aff" rid="A4">4</xref><xref ref-type="aff" rid="A5">5</xref></contrib><contrib contrib-type="author"><name><surname>Spencer</surname><given-names>James</given-names></name><xref ref-type="aff" rid="A1">1</xref><xref ref-type="corresp" rid="CR1">*</xref></contrib><aff id="A1"><label>1</label>School of Cellular and Molecular Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0524sp257</institution-id><institution>University of Bristol</institution></institution-wrap>, <city>Bristol</city>, <country country="GB">United Kingdom</country>, <postal-code>BS8 1TD</postal-code>, U.K</aff><aff id="A2"><label>2</label>Centre for Computational Chemistry, School of Chemistry, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0524sp257</institution-id><institution>University of Bristol</institution></institution-wrap>, <country country="GB">United Kingdom</country>, <postal-code>BS8 1TS</postal-code>, U.K</aff><aff id="A3"><label>3</label>Department of Life Sciences, 4 South, Claverton Down, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/002h8g185</institution-id><institution>University of Bath</institution></institution-wrap>, <postal-code>BA2 7AY</postal-code>, <country country="GB">U.K</country></aff><aff id="A4"><label>4</label>Department of Chemistry, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap>, <addr-line>12 Mansfield Road</addr-line>, <city>Oxford</city><postal-code>OX1 3TA</postal-code>, <country country="GB">U.K</country></aff><aff id="A5"><label>5</label>Ineos Oxford Institute for Antimicrobial Research, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap>, <addr-line>12 Mansfield Road</addr-line>, <city>Oxford</city>, <postal-code>OX1 3TA</postal-code><country country="GB">U.K</country></aff></contrib-group><author-notes><corresp id="CR1">
<label>*</label>Corresponding author: <email>Jim.Spencer@bristol.ac.uk</email>
</corresp></author-notes><pub-date pub-type="nihms-submitted"><day>02</day><month>11</month><year>2024</year></pub-date><pub-date pub-type="preprint"><day>30</day><month>10</month><year>2024</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">CC BY-NC-ND 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Carbapenemases, β-lactamases hydrolysing carbapenem antibiotics, severely challenge treatment of multi-drug resistant bacterial infections. OXA-48 is among the most widely disseminated carbapenemases in <italic>Enterobacterales</italic>, consequently new treatment options for OXA-48 producers are urgently required. Development of diazabicyclooctane (DBO) inhibitors to overcome β-lactamase-mediated resistance is one attractive option, due to their efficacy against a wide range of β-lactamases. The DBO avibactam is already licensed for clinical use, with the related compound nacubactam currently in phase III trials for carbapenem-resistant infections. Here we investigate the activities of avibactam and nacubactam towards OXA-48 and two variants, OXA-163 and OXA-405, that contain deletions in the β5 - β6 loop adjacent to the active site and show modified activity towards different β-lactam classes. Compared to avibactam, nacubactam is c. 80-fold less potent towards OXA-48, but this difference is reduced in OXA-163 and OXA-405. Crystal structures of the respective avibactam and nacubactam complexes, and molecular dynamics simulations based upon these, reveal residue Arg214 on the OXA-48 β5 - β6 active-site loop to be electrostatically repelled by nacubactam, but not avibactam, binding. This increases flexibility of the OXA-48 β5 – β6 loop, as well as neighbouring active site loops, in simulations of the OXA-48:nacubactam, compared to the avibactam, complex. Such effects are not observed in simulations of the respective complexes of OXA-163 and OXA-405, which lack Arg214. These data indicate that interactions with Arg214 can determine DBO potency towards OXA-48-like enzymes, and suggest that sequence variation in this β-lactamase family affects reactivity towards inhibitors as well as β-lactam substrates.</p></abstract><kwd-group><kwd>β-lactamase</kwd><kwd>carbapenemase</kwd><kwd>OXA-48</kwd><kwd>diazabicyclooctane</kwd><kwd>crystal structure</kwd><kwd>molecular dynamics</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Antimicrobial resistance (AMR) is a major and increasing threat to global public health, with 8.2 million associated annual deaths predicted by 2050<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. The β-lactams (penicillins and related agents) are the most commonly prescribed antibiotic class<sup><xref ref-type="bibr" rid="R2">2</xref>,<xref ref-type="bibr" rid="R3">3</xref></sup>. In Gram negative bacteria, the dominant β-lactam resistance mechanism is expression of β-lactamase enzymes<sup><xref ref-type="bibr" rid="R4">4</xref></sup> that hydrolyse the four-membered β-lactam ring (<xref ref-type="fig" rid="F1">Fig. 1</xref>), to render β-lactams inactive towards their cellular targets, the penicillin-binding proteins (PBPs). β-Lactamases are divided, on the basis of sequence and structure, into four mechanistically distinct classes (A to D) of which classes A, C and D are serine β-lactamases (SBLs) and class B zinc-dependent metallo-β-lactamases (MBLs)<sup><xref ref-type="bibr" rid="R5">5</xref></sup>. OXA-48 is a class D SBL that uses a catalytic serine nucleophile (Ser70) to break down β-lactam substrates, with a proximal post-translationally carbamylated lysine (Lys73) proposed to act as the general base for both the acylation and deacylation steps of the hydrolysis reaction<sup><xref ref-type="bibr" rid="R6">6</xref></sup>.</p><p id="P3">OXA-48 is of particular clinical importance due to its prevalence in the <italic>Enterobacterales</italic> order of bacteria, which includes two (<italic>Escherichia coli</italic> and <italic>Klebsiella pneumoniae</italic>) of the three pathogens most commonly associated with AMR-related deaths globally in 2019<sup><xref ref-type="bibr" rid="R7">7</xref></sup>. Worryingly, OXA-48 production causes failure of carbapenems, the class of β-lactam antibiotics reserved for the most serious bacterial infections. Due to its widespread dissemination, OXA-48 is regarded as one of the five most important acquired β-lactamases responsible for carbapenem resistance<sup><xref ref-type="bibr" rid="R8">8</xref>,<xref ref-type="bibr" rid="R9">9</xref></sup>. Carbapenem resistant <italic>Enterobacterales</italic> are classed by the World Health Organization as Critical Priority pathogens for global public health<sup><xref ref-type="bibr" rid="R10">10</xref></sup>.</p><p id="P4">To circumvent β-lactamase-mediated antibiotic resistance, β-lactamase inhibitors (BLIs) have been developed for co-administration with β-lactams<sup><xref ref-type="bibr" rid="R4">4</xref></sup>. The diazabicyclooctanes (DBOs) are one group of BLIs that have proven successful in the clinic, with avibactam currently used in combination with the expanded-spectrum oxyiminocephalosporin ceftazidime to treat multi-drug resistant bacterial infections (<xref ref-type="fig" rid="F1">Fig. 1</xref>)<sup><xref ref-type="bibr" rid="R11">11</xref></sup>. DBOs inhibit SBLs through covalent attachment to the nucleophilic serine by a reversible carbamoylation reaction, and evade hydrolysis by recyclising to release the intact DBO (<xref ref-type="fig" rid="F2">Fig. 2</xref>)<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R13">13</xref></sup>.</p><p id="P5">DBO inhibitors are of particular interest in the context of OXA-48, as this enzyme is generally poorly inhibited by more “classical” β-lactam-based inhibitors (tazobactam, clavulanic acid, sulbactam) but more effectively by avibactam<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R17">17</xref></sup>. In all currently available crystal structures of OXA-48 complexes, avibactam shows a very similar binding mode, and appears to induce decarbamylation of the catalytic Lys73, even under basic conditions, which has been attributed to the potency of avibactam inhibition towards class D carbapenemases<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref>,<xref ref-type="bibr" rid="R18">18</xref></sup>. However, Fröhlich <italic>et al</italic>.<sup><xref ref-type="bibr" rid="R11">11</xref></sup> demonstrated that resistance to the ceftazidime:avibactam combination could be achieved in the laboratory through just two amino acid changes in the OXA-48 active site, highlighting the potential for changes in susceptibility to DBO combinations to emerge in clinical OXA-48 variants, and the need for continued inhibitor development to guard against such a possibility.</p><p id="P6">Following the development and introduction of avibactam<sup><xref ref-type="bibr" rid="R13">13</xref></sup>, numerous additional DBO inhibitors have been investigated, that largely differ in the composition of the C2 substituent group on the core DBO scaffold<sup><xref ref-type="bibr" rid="R19">19</xref>–<xref ref-type="bibr" rid="R21">21</xref></sup>. One such inhibitor, nacubactam, differs from avibactam by the addition of a 1-aminoethoxy group on the C2 group (<xref ref-type="fig" rid="F1">Fig. 1</xref>), and is currently in phase III clinical trials in combination with β-lactams cefepime or aztreonam for the treatment of complicated urinary tract infections or uncomplicated pyelonephritis (<ext-link ext-link-type="uri" xlink:href="https://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> identifier NCT05887908)<sup><xref ref-type="bibr" rid="R22">22</xref></sup>. We have investigated activity of nacubactam, in comparison with avibactam, towards OXA-48 and two clinical variants, OXA-163 and OXA-405, that contain four amino acid deletions within their β5 – β6 active site loops and show reduced carbapenemase activity but enhanced hydrolysis of ceftazidime and other oxyiminocephalosporins. A combination of <italic>in vitro</italic> inhibition assays, X-ray crystal structures of enzyme:DBO complexes, and molecular dynamics simulations based upon these leads us to conclude that electrostatic repulsion between the positively charged N atom of the nacubactam C2 substituent and the side-chain of Arg214 on the β5 – β6 loop reduces potency towards OXA-48, compared to avibactam. These effects are less pronounced in the OXA-163 and OXA-405 variants, which lack Arg214. These data indicate that the effects of variation between OXA-48-like β-lactamases extend to interactions with DBO inhibitors, as well as classes of β-lactam substrates<sup><xref ref-type="bibr" rid="R23">23</xref>–<xref ref-type="bibr" rid="R25">25</xref></sup>.</p></sec><sec id="S2" sec-type="results"><title>Results</title><sec id="S3"><title>DBO interactions with the OXA-48 and its β5 – β6 loop variants, OXA-163 and OXA-405</title><p id="P7">In this work, we sought to investigate the effects of DBO inhibitors upon naturally occurring OXA-48 variants differing in their activity towards expanded-spectrum oxyiminocephalosporin (e.g. ceftazidime) and carbapenem substrates. To understand the effect of β5 – β6 loop composition on DBO inhibition, we undertook <italic>in vitro</italic> inhibition experiments challenging OXA-48 and its naturally occurring variants, OXA-163 and OXA-405, with the DBO inhibitors avibactam and nacubactam, which is distinguished from avibactam by an extended C2 substituent bearing a 1-aminoethoxy group. Both OXA-163 and OXA-405 have four amino acid deletions within the β5 – β6 loop, including of residue Arg214. OXA-163 also has a single amino acid substitution (Ser212Asp) adjacent to the deleted region. Compared to avibactam, nacubactam is a weaker inhibitor of OXA-48, with respective IC<sub>50</sub> values of 19.91 µM and 0.26 µM, indicating a 77-fold difference in inhibition potency (<xref ref-type="table" rid="T1">Table 1</xref>). Although avibactam remains more potent than nacubactam towards both OXA-163 (IC<sub>50</sub> values 0.20 µM and 1.23 µM, respectively) and OXA-405 (IC<sub>50</sub> values 0.99 µM and 10.6 µM, respectively) for both variants there are notable increases in nacubactam inhibition potency compared to OXA-48 (16.2-fold for OXA-163, 1.9-fold for OXA-405). Moreover, the differences in inhibition potencies between avibactam and nacubactam are also reduced for the two variants (6.2- and 10.7-fold for OXA-163 and OXA-405, respectively). Therefore, the extended β5 – β6 loop of OXA-48 appears deleterious for the inhibition potency of nacubactam, compared to both OXA-163 and OXA-405.</p><p id="P8">However, minimum inhibitory concentration (MIC) values show nacubactam can better potentiate β-lactams ertapenem and ceftazidime against laboratory and control <italic>E. coli</italic> strains expressing these enzymes (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>). In fact, nacubactam reduces MICs at least 4-fold more greatly when combined with ertapenem and ceftazidime against <italic>E. coli</italic> expressing OXA-48, compared to avibactam. In contrast, nacubactam when combined with meropenem gives a 4-fold higher MIC value compared to meropenem with avibactam against OXA-48-producing <italic>E. coli</italic>, whereas more similar MICs are observed for the meropenem-avibactam combination against <italic>E. coli</italic> expressing OXA-163 and OXA-405, corroborating with IC<sub>50</sub> observations.</p></sec><sec id="S4"><title>Crystal structure of OXA-48:nacubactam carbamoyl-enzyme complex</title><p id="P9">To understand the basis for these differences in DBO inhibition potency towards OXA-48 and the two variants in more detail, we sought to determine crystal structures for the respective complexes, comparing as appropriate with pre-existing structures. The crystal structure of nacubactam bound to OXA-48 was solved at 1.51 Å resolution with the enzyme assembled as a homodimer and a chloride ion positioned at the dimer interface, as characterised previously (<xref ref-type="fig" rid="F3">Fig. 3A</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S2</xref>)<sup><xref ref-type="bibr" rid="R26">26</xref></sup>. Continuous positive <italic>F</italic><sub>o</sub>-<italic>F</italic><sub>c</sub> electron density between the ligand and Ser70 indicates the presence of a covalently bound nacubactam-derived carbamoyl-enzyme complex (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). When overlaid upon the structures of uncomplexed OXA-48 (1.38 Å resolution, <xref ref-type="supplementary-material" rid="SD1">Table S2</xref>) and OXA-48 bound to avibactam (PDB 4S2K<sup><xref ref-type="bibr" rid="R14">14</xref></sup>, 2.10 Å), all three structures have very similar backbones, as highlighted by the low Cα RMSD values when aligned (0.41 Å and 0.53 Å for superposition of the OXA-48:nacubactam complex on the uncomplexed and avibactam-bound structures, respectively, as calculated in PyMOL). The avibactam and nacubactam carbamoyl-enzyme complexes show a similar binding modes to OXA-48, with the C7 carbonyl group positioned within the oxyanion hole formed by the backbone amides of residues Ser70 and Tyr211, as seen in β-lactam-derived acyl-enzyme complexes of OXA-48-like enzymes (<xref ref-type="fig" rid="F3">Fig. 3C</xref>)<sup><xref ref-type="bibr" rid="R6">6</xref></sup>. Both complexes also show the DBO sulphonate group pointing towards the side chains of residues Arg250 and Thr209, with the side chain hydroxyl of Ser118 within hydrogen bonding distance of the DBO N6. Thus, binding of the DBO core is facilitated by complementary electrostatic and hydrogen-bonding interactions, whilst the respective C2 substituents point out of the active site towards the OXA-48 β5 - β6 (residues 212 - 219) and Ω-(residues 144 - 163) loops.</p><p id="P10">One noticeable difference between the active site arrangements of these complexes is the carbamylation status of Lys73, which is decarbamylated in both DBO-bound structures (determined at pH values of 8.8 and 7.5 for the nacubactam and avibactam complexes, respectively, <xref ref-type="supplementary-material" rid="SD1">Table S3</xref>), but remains carbamylated in the uncomplexed enzyme (structure determined at pH 7.5, <xref ref-type="supplementary-material" rid="SD1">Fig. S1, Table S3</xref>)<sup><xref ref-type="bibr" rid="R14">14</xref></sup>. An additional difference is in the positioning of the side chain of residue Leu158 in the active-site Ω-loop, which adopts a <italic>g-</italic> χ<sub>1</sub> side-chain rotamer in the avibactam complex, whereas the <italic>t</italic> rotamer is observed in uncomplexed and nacubactam-bound OXA-48 (<xref ref-type="fig" rid="F3">Fig. 3</xref>). It is likely that Leu158 adopts this conformation to avoid steric clashes with the bulkier C2 substituent of nacubactam, compared to avibactam. As Leu158 is part of the so-called ‘deacylating water-channel’, differences are observed in solvent access to the hydrophobic pocket in which Lys73 resides (<xref ref-type="fig" rid="F3">Fig. 3D</xref>)<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref></sup>. Surface views suggest that when Leu158 is in the <italic>t</italic> rotamer, as in the avibactam complex, this channel is open, as evidenced by presence of a water (W1) proximal to the C7 carbonyl of the carbamoyl-enzyme complex. In contrast, when Leu158 adopts the <italic>g-</italic> rotamer, observed when nacubactam is bound, the channel is closed, and the adjacent water is modelled in dual occupancy with the Leu158 side-chain due to steric clashes (Leu158 Cδ2 is ~1.8 Å away from the position of this water molecule) (<xref ref-type="fig" rid="F3">Fig. 3D</xref>).</p><p id="P11">In the active site of chain B, Arg214 of the Ω-loop adopts a dual conformation when OXA-48 is bound to nacubactam. In both conformations, the Arg214 side chain is poorly resolved in the final 2<italic>F</italic><sub>o</sub>-<italic>F</italic><sub>c</sub> electron density map (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>). Thus, it is possible that the side-chain of Arg214 and the C2 tail nitrogen of nacubactam are electrostatically repelled <italic>in crystallo</italic> as a result of their clashing positive charges. Chain A of the nacubactam complex, in contrast, does not show this effect, most likely due to a crystal packing artefact whereby residue Glu132 from an adjacent molecule not in the asymmetric unit can electrostatically interact with Arg214, thus holding it in place. Consequently, the C2 tail group of nacubactam adopts a dual conformation in the chain A active site, presumably as a result of electrostatic repulsion by the Arg214 side-chain. Of note, in these experiments OXA-48 was purified and crystallised under basic conditions (purification buffer pH 8.4, crystallisation solution pH 8.8) but it is very likely that both Arg214 and the nitrogen atom of the nacubactam C2 substituent are protonated at physiological pH. Indeed, the predicted pKa of Arg214 is 12.2 (PropKa webserver<sup><xref ref-type="bibr" rid="R29">29</xref></sup>) and that of the nacubactam C2 aminoethoxy nitrogen 8.7 - 9.1 (AIMNet2/MolGpka webservers<sup><xref ref-type="bibr" rid="R30">30</xref>,<xref ref-type="bibr" rid="R31">31</xref></sup>, <xref ref-type="supplementary-material" rid="SD1">Fig. S3</xref>).</p></sec><sec id="S5"><title>MM MD simulations of DBO-derived carbamoyl-enzyme complexes</title><p id="P12">To investigate the possibility that these differences between avibactam and nacubactam binding affect the dynamic behaviour of OXA-48, MM MD was next used to simulate uncomplexed, avibactam- and nacubactam-bound OXA-48. Root mean-squared deviation (RMSD) plots indicate that all simulations were stable over total trajectories of 1.5 µs (<xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>). Pairwise differences in average root mean-square fluctuation (ΔRMSF) for each residue, across both active sites of the OXA-48 dimer, were then calculated between the different simulations (<xref ref-type="fig" rid="F4">Fig. 4</xref>). When comparing simulations of the two DBO-bound complexes, three regions of the OXA-48 sequence, the Ω- (residues 144 - 163), β5 – β6 (212 - 219) and β7 – α10 (240 - 247) loops show noticeable changes in ΔRMSF (<xref ref-type="fig" rid="F4">Fig. 4A</xref>). When mapped onto the structure of OXA-48, these regions of difference are centred around Arg214, which has an average ΔRMSF of +0.41 Å. This indicates an increase in mobility of this residue in the nacubactam, compared to the avibactam complex, consistent with our crystallographic evidence (above) of electrostatic clashes between the nacubactam C2 substituent and the β5 – β6 loop (<xref ref-type="fig" rid="F3">Fig. 3C</xref>). Indeed, measuring the distance between Arg214 (Cζ) and the C2 amide nitrogen atoms of each DBO inhibitor over the respective simulation trajectories reveals that this distance is generally longer, with Arg214 adopting a more variable position, in the nacubactam-, compared to the avibactam-bound, complex (<xref ref-type="supplementary-material" rid="SD1">Fig. S5</xref>).</p><p id="P13">In addition, further simulations of the OXA-48:nacubactam complex, in which the C2 aminoethoxy nitrogen was deprotonated (<xref ref-type="supplementary-material" rid="SD1">Figures S4, S5</xref>), do not show the same degree of repulsion of Arg214, suggesting that the observed displacement is largely due to electrostatic effects.</p><p id="P14">Arg214 displacement by nacubactam results in an increase in flexibility across adjacent loops in the OXA-48 active site, most notably within the β5 - β6 loop itself and, by disruption of a salt bridge with Asp159, across the Ω-loop (<xref ref-type="fig" rid="F4">Fig. 4B</xref>). The β7 – α10 loop, which does not directly interact with bound DBO inhibitors in carbamoyl-enzyme complexes, also appears to be destabilised by increased movement of the β5 – β6 loop. When compared to simulations of uncomplexed OXA-48, the nacubactam-bound complex shows similar RMSF differences to those obtained from comparison with the avibactam complex. In contrast, such differences are less prominent when the avibactam-bound structure is compared with that of uncomplexed OXA-48, although the Arg214 RMSF increases slightly in the former. However, this does not noticeably affect the stability of neighbouring loops in the same way as was observed for nacubactam-bound, compared to uncomplexed, OXA-48.</p><p id="P15">In contrast, Leu158, on the Ω-loop, appears more flexible when avibactam is bound, compared to uncomplexed and nacubactam-bound OXA-48. In simulations of nacubactam-bound OXA-48 Leu158 predominantly adopts the <italic>g-</italic> χ<sub>1</sub> rotamer, as observed in the crystal structure (<xref ref-type="supplementary-material" rid="SD1">Fig. S6A</xref>). In contrast, in the avibactam-bound or uncomplexed structures the <italic>t</italic> rotamer is preferred. Conformation of the Leu158 side-chain is therefore specifically limited in the nacubactam-bound complex, as a result of steric restrictions imposed by its larger C2 substituent, compared to that of avibactam, as observed <italic>in crystallo</italic> (<xref ref-type="fig" rid="F3">Fig. 3D</xref>). In contrast, Val120, the other residue contributing to the OXA-48 deacylating water channel<sup><xref ref-type="bibr" rid="R27">27</xref>,<xref ref-type="bibr" rid="R28">28</xref></sup>, consistently adopts the <italic>t</italic> rotamer, as observed in the crystal structures, in all simulations of the uncomplexed and DBO-bound enzyme (<xref ref-type="supplementary-material" rid="SD1">Fig. S6B</xref>).</p></sec><sec id="S6"><title>DBO complexes with OXA-48 variants OXA-163 and OXA-405</title><p id="P16">Crystal structures were next obtained for the OXA-48 variants OXA-163 and OXA-405, as uncomplexed enzymes and in the nacubactam- and avibactam- bound forms (<xref ref-type="supplementary-material" rid="SD1">Table S2, Fig. S7</xref>). Both enzymes assemble as homodimers in the asymmetric unit and, consistent with their high overall sequence identities, adopt very similar global structures and active site arrangements to OXA-48. The exception is the Ser70 nucleophile, which is in dual conformation in one of the two chains in the crystallographic dimers of uncomplexed OXA-163 and OXA-405 (<xref ref-type="supplementary-material" rid="SD1">Fig. S8A, B</xref>). The respective protein backbones only differ at the β5 – β6 loop, which is truncated in the cases of OXA-163 and OXA-405, compared to OXA-48 (<xref ref-type="supplementary-material" rid="SD1">Fig. S8C</xref>). Part of the OXA-405 β7 – α10 loop, which neighbours the β5 – β6 loop, could not be modelled due to weak electron density, indicating that this loop is more mobile in uncomplexed OXA-405, compared to the other enzymes. Lys73 is fully decarbamylated in all DBO-bound structures except the OXA-405:avibactam (both chains) and OXA-163:avibactam (only in chain A) complexes, where Lys73 is modelled as partially carbamylated (<xref ref-type="supplementary-material" rid="SD1">Table S4A</xref>), in dual-occupancy with a free lysine side-chain that is associated with either a water molecule or chloride ion (<xref ref-type="fig" rid="F5">Fig. 5A</xref>).</p><p id="P17">In chain B of the OXA-405:nacubactam complex Tyr211 adopts a dual conformation (<xref ref-type="fig" rid="F5">Fig. 5B</xref>). The presence of an alternative side-chain rotamer coincides with poor electron density for the β7 – α10 loop, as also seen in uncomplexed OXA-405 (<xref ref-type="supplementary-material" rid="SD1">Fig. S9</xref>). Furthermore, Leu243 of the β7 – α10 loop also adopts multiple conformations to avoid steric clashes with the Tyr211 side chain. In contrast, in the active site of chain A in the OXA-405:nacubactam complex, residues Tyr211 and Leu243 are each in a single conformation and the β7 – α10 loop can be modelled in its entirety.</p><p id="P18">In the respective carbamoyl-enzyme complexes with OXA-405 and OXA-163 nacubactam and avibactam adopt similar binding modes to those observed for the OXA-48 parent enzyme (<xref ref-type="fig" rid="F5">Fig. 5A, B</xref>), characterised by complementary electrostatic interactions between the DBO sulphonate group and Arg250 (OXA-48 numbering) and positioning of their C2 tail groups close to the β5 – β6 loop. The C2 substituent of avibactam is identically positioned in all three enzymes, whereas the additional 1-aminoethoxy group of nacubactam appears more variably located across these structures. Indeed, the unbiased electron density for this extended substituent of nacubactam is less well defined compared to that for the C2 amide component common to the two DBOs, suggesting that in all three enzymes the nacubactam C2 substituent is much more flexible than is the case for avibactam (<xref ref-type="supplementary-material" rid="SD1">Fig. S7</xref>).</p><p id="P19">Residue Leu158 appears to adopt an alternative rotamer (<italic>g-</italic>) when avibactam is bound to OXA-163 (chain B) and OXA-405, compared to OXA-48 or chain A of the OXA-163:avibactam complex where the <italic>t</italic> rotamer is observed. In contrast, when nacubactam is bound, Leu158 is in the <italic>g-</italic> rotamer for OXA-48 and OXA-163, whilst in the OXA-405:nacubactam complex both rotamers are observed across the two active sites. Thus, the relationship between the conformation of Leu158, the composition of the β5 – β6 loop, and susceptibility to DBO inhibition appears to be structurally complex in the context of OXA-48-like enzymes.</p></sec><sec id="S7"><title>MM MD simulations of DBO-bound OXA-163 and OXA-405 complexes</title><p id="P20">MM MD simulations of uncomplexed, avibactam- and nacubactam-bound OXA-163 and OXA-405 were then run, using the same protocol as for OXA-48. RMSD plots (<xref ref-type="supplementary-material" rid="SD1">Fig. S4</xref>) indicate all simulations to be stable over their respective trajectories. ΔRMSF analysis reveals no noticeable differences in the flexibility of the β5 - β6 loop between simulations of avibactam- and nacubactam-bound OXA-163 and OXA-405 (<xref ref-type="fig" rid="F5">Fig. 5C, D</xref>). The Ω-loop appears slightly more flexible in nacubactam-, compared to avibactam-bound, OXA-163, although the difference is less marked than is the case for OXA-48 (<xref ref-type="fig" rid="F4">Fig. 4B</xref>). The β7 - α10 loop, in contrast, is much more stable in both of the nacubactam, compared to the avibactam, complexes. This corresponds with a reduction in mobility of Tyr211, suggesting that in OXA-163 and OXA-405 nacubactam can stabilise this residue much more readily than does avibactam. This in turn may affect the dynamics of the β7 - α10 loop, consistent with our crystal structures (<xref ref-type="supplementary-material" rid="SD1">Fig. S9</xref>). Indeed, residue Leu243, which is shown to be dislodged by conformational changes of Tyr211 in the crystal structure of OXA-405 bound to nacubactam, is much more stable in both cases.</p><p id="P21">Ser118 is suggested to play an important role in DBO turnover by SBLs<sup><xref ref-type="bibr" rid="R14">14</xref>,<xref ref-type="bibr" rid="R15">15</xref></sup>. Proposed reaction mechanisms for class D SBLs suggest that Ser118 can deprotonate the N6 atom of the DBO carbamoyl-enzyme to promote intramolecular recyclisation, and may also contribute to activation of the decarbamoylating water for hydrolysis<sup><xref ref-type="bibr" rid="R6">6</xref>,<xref ref-type="bibr" rid="R12">12</xref></sup>. Therefore, the distances between the DBO N6 and Ser118 Oγ atoms were measured during our MM MD simulations, and the percentage of simulation frames where this distance is within an arbitrarily selected 3.5 Å cutoff calculated (<xref ref-type="fig" rid="F6">Fig. 6</xref>). No major differences in these percentage values were observed between the two independently modelled active sites in the various dimeric complexes, with the largest difference 11.2% between chains A and B in the simulation of avibactam-bound OXA-163. However, the simulations revealed that, in complexes of OXA-48, OXA-163 and OXA-405, the N6 of nacubactam was more frequently positioned close to the Ser118 side chain than was the case for avibactam. These differences, when averaged across both active site complexes, are greatest for OXA-163 (44.0%), followed by OXA-405 (34.4%), with OXA-48 showing the smallest difference in the Ser118:DBO N6 distance between the avibactam- and nacubactam-bound complexes (17.5%). However, in simulations of the OXA-48:nacubactam complex in which the N of the nacubactam C2 substituent is deprotonated, the distance between Ser118 and the DBO nitrogen N6 is consistently greater than in any of the other enzyme:DBO complexes studied here, with these atoms positioned within 3.5 Å of each other in only 10.1% of simulation frames. This analysis suggests that protonation of the nacubactam C2 tail group is required for positioning close to Ser118, and can consequently affect the propensity for recyclisation.</p></sec></sec><sec id="S8" sec-type="discussion"><title>Discussion</title><p id="P22">OXA-48 has become one of the most commonly detected carbapenemases in <italic>Enterobacterales</italic> globally, thus treatment options that circumvent β-lactam antibiotic resistance as a result of OXA-48-production are of clinical importance<sup><xref ref-type="bibr" rid="R8">8</xref></sup>. DBO-based BLIs are an established option, and various efforts have been made to optimise their activity, with multiple compounds having modified C2 substituents compared to avibactam, the original DBO now available in the clinic<sup><xref ref-type="bibr" rid="R4">4</xref></sup>. The degree of modification to the C2 substituent appears to correlate with intrinsic antimicrobial, as well as β-lactamase inhibitory, activity resulting from the ability to bind to both PBPs and SBLs. This gives rise to the possibility of a ‘dual-action’ agent that would not require combination with a β-lactam for treatment of antibiotic-resistant infections<sup><xref ref-type="bibr" rid="R32">32</xref>,<xref ref-type="bibr" rid="R33">33</xref></sup>. Indeed, nacubactam, which compared to avibactam has an extended 1-aminoethoxy group on its C2 substituent, has been shown to have some antimicrobial activity, attributed to its ability to inhibit PBP2 in <italic>Enterobacterales</italic><sup><xref ref-type="bibr" rid="R22">22</xref></sup>.</p><p id="P23">Here, we have biochemically and structurally characterised inhibition by nacubactam, in comparison with avibactam, of OXA-48 and its naturally occurring variants OXA-163 and OXA-405. IC<sub>50</sub> values show nacubactam to be a substantially weaker inhibitor of OXA-48 than avibactam, whereas differences in the potencies of the two DBOs decrease in OXA-163 and OXA-405, which both have four amino acid deletions in the β5 – β6 active site loop. However, we observe potency differences in IC<sub>50</sub> and MIC experiments. This could be due to the improved cell uptake of nacubactam and/or its propensity to inhibit PBP2 that may enhance β-lactam action, as seen by a reduction in MICs against non-β-lactamase-producing lab/control strains (<xref ref-type="supplementary-material" rid="SD1">Table S1</xref>)<sup><xref ref-type="bibr" rid="R22">22</xref></sup>.</p><p id="P24">We determined high-resolution crystal structures of uncomplexed, avibactam- and nacubactam-bound OXA-48, OXA-163 and OXA-405 to investigate how differences in β5 – β6 loop composition relate to DBO potency. This revealed conformational variability of this loop only in the OXA-48:nacubactam complex, as a result of electrostatic repulsion between the C2 tail nitrogen of the nacubactam 1-aminoethoxy group and the side chain of Arg214. Subsequent MM MD simulations of these structures reveal increased flexibility of the β5 – β6 loop in nacubactam-bound OXA-48, likely due to DBO-mediated electrostatic displacement of Arg214, which consequently appears to propagate flexibility in neighbouring active site loops. Such an effect has also been shown in a structure of OXA-48 in complex with the oxyimino-cephalosporin antibiotic ceftazidime (PDB 6Q5F), where the extra bulk of the ceftazidime oxyimino group (<xref ref-type="fig" rid="F1">Fig. 1</xref>) appears to disrupt the interaction between Arg214 and Asp159, which the authors suggest increases flexibility of the Ω-loop, as evidenced by a lack of electron density for this region in the crystal structure<sup><xref ref-type="bibr" rid="R11">11</xref></sup>. Therefore, it appears that Arg214 is an important determinant of OXA-48 active site conformational flexibility, and its displacement may begin to explain the weaker IC<sub>50</sub> value of nacubactam towards OXA-48, compared to avibactam.</p><p id="P25">We note, however, that nacubactam potency is not fully restored to levels observed for avibactam when Arg214 is deleted, as in OXA-163 and OXA-405, suggesting that additional factors can affect DBO potency towards these enzymes. In fact, in MM MD simulations of all three enzymes, we see a greater propensity for nacubactam, compared to avibactam, to adopt a binding pose that may more readily facilitate DBO recyclisation, as indicated by the closer proximity of the DBO N6 nitrogen and the Ser118 side-chain oxygen. Thus, it is possible that, compared to avibactam, nacubactam is more readily recyclised by OXA-48-related enzymes, therefore reducing its inhibitory potency by reducing the lifetime of the carbamoyl-enzyme complex.</p><p id="P26">We also see differences between the various complexes of OXA-48 family members, in both crystal structures and in simulations, in the positioning of residue Leu158 in the deacylating water channel. It appears that steric considerations with respect to the extended C2 1-aminoethoxy substituent of nacubactam restrict the flexibility of Leu158, thus resulting in a closed deacylating water channel when OXA-48 is bound to nacubactam. This may affect solvent accessibility of the hydrophobic pocket in which Lys73 resides, in turn influencing the carbamylation status of Lys73 due to the requirement for water access to mediate lysine decarbamylation<sup><xref ref-type="bibr" rid="R12">12</xref>,<xref ref-type="bibr" rid="R34">34</xref>–<xref ref-type="bibr" rid="R36">36</xref></sup>. This has been observed in time-resolved crystallographic studies of avibactam carbamoylation in the class D SBL CDD-1, that show corresponding movement of Leu158 and release of carbon dioxide following Lys73 decarbamylation<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. The consequence, for DBO susceptibility, of Leu158 side-chain position and Lys73 carbamylation status is likely to be complex due to the multiple DBO turnover pathways that can occur in class D SBLs (<xref ref-type="fig" rid="F2">Fig. 2</xref>)<sup><xref ref-type="bibr" rid="R12">12</xref></sup>. Indeed, the variability of Leu158 rotamers in our crystal structures of DBO complexes with OXA-163 and OXA-405 highlights this.</p><p id="P27">In conclusion, this work suggests a structural relationship between DBO inhibitory potency and β5 - β6 active site loop composition in class D β-lactamases of the OXA-48 family. Our findings thus suggest that, while variants differ in susceptibility to individual DBOs, rational design strategies involving optimising C2 substituents to make more favourable interactions with the active site is one route to more potent DBO inhibitors of OXA-48 family members.</p></sec><sec id="S9" sec-type="methods"><title>Methods</title><sec id="S10"><title>Recombinant enzyme expression and purification</title><p id="P28">For crystallography and kinetic experiments, genes encoding the mature OXA-163<sup>23-261</sup> and OXA-405<sup>23-265</sup> open reading frames were synthesised (Eurofins Genomics), amplified by PCR and cloned into the pOPINF T7 expression vector by recombination (InFusion, Takara) using primers listed in <xref ref-type="supplementary-material" rid="SD1">Table S5</xref><sup><xref ref-type="bibr" rid="R37">37</xref></sup>. <italic>E. coli</italic> BL21-DE3 cells (Novagen) were transformed with pOPINF-OXA-48<sup>(23-265)</sup> (previously cloned as described<sup><xref ref-type="bibr" rid="R38">38</xref></sup>), pOPINF-OXA-163<sup>(23-261)</sup> and pOPINF-OXA-405<sup>(23-261)</sup> by heat shock and grown in 2X YT broth supplemented with 50 µg.mL<sup>-1</sup> carbenicillin (Fisher Scientific) for large scale growth (37 °C, 180 rpm shaking). When the culture reached an OD<sub>600</sub> of 0.6 – 0.8, enzyme expression was induced with the addition of 0.5 mM IPTG (Calibre Scientific) and left overnight at 18 °C, 180 rpm shaking. Cells were then pelleted by centrifugation (6500 × <italic>g</italic>, 10 minutes) and resuspended in 50 mL of the respective purification buffer (50 mM Tris pH 8.4, 0.25 M NaCl, 20% Glycerol (OXA-48); 150 mM HEPES pH 8.0, 0.4 M NaCl (OXA-163); or 150 mM HEPES pH 6.5, 0.4 M NaCl (OXA-405)) supplemented with 10 mM imidazole, 1 tablet of cOmplete EDTA-free protease inhibitor cocktail (Roche), 1 µL Benzonase Endonuclease (Novagen) and 2 - 5 mg lysozyme (Sigma). All subsequent purification steps were completed at 4 °C or on ice. Cells were lysed by a cell disruptor (Constant Systems) at 25 kpsi and centrifuged at 100,000 × <italic>g</italic> for 1 hour. The soluble fraction was then added to 4 mL Ni-NTA beads (Qiagen) pre-washed in water, and incubated for 1 hour with rotation. The beads were washed once with 10 mL of the respective purification buffer supplemented with 10 mM imidazole, and once more with 10 mL purification buffer supplemented with 20 mM imidazole. Protein was then eluted and collected with the addition of 10 mL of the respective purification buffer supplemented with 300 mM imidazole. NaCl was omitted from the elution step for OXA-163 and OXA-405. The eluent was buffer-exchanged to reduce the imidazole concentration to less than 50 mM using a 10 kDa cutoff Vivaspin Centrifugal Concentrator (Sartorius), and subsequently incubated overnight with 2 mg recombinant 6His-tagged 3C protease to cleave the enzyme purification tag. The mixture was run through a second 10 mL Ni-NTA (nitrilotriacetic acid) column to remove 3C protease and cleaved hexhistidine tags, and the eluent from this column collected, concentrated to 5 mL and loaded onto a 120 mL HiLoad 16/600 Superdex 75 size-exclusion column (Cytiva) equilibrated with OXA-48 purification buffer, or 0.1 M sodium phosphate buffer at pH 8.0 or pH 6.5 for OXA-163 or OXA-405, respectively. Peak fractions were collected (purity determined by SDS-PAGE<sup><xref ref-type="bibr" rid="R39">39</xref></sup>), pooled and concentrated to 11.5 mg.mL<sup>-1</sup> (OXA-48), 7.7 mg.mL<sup>-1</sup> (OXA-163) or 11.1 mg.mL<sup>-1</sup> (OXA-405). Enzyme concentration was measured using a NanoDrop spectrophotometer (ThermoFisher) with extinction coefficients calculated using Expasy ProtParam<sup><xref ref-type="bibr" rid="R40">40</xref></sup>. Final samples were snap-frozen in liquid nitrogen and stored at -80 °C.</p></sec><sec id="S11"><title>Ligand soaking and crystal structure determination</title><p id="P29">The structure of unliganded OXA-48 was determined using diffraction data collected from crystals that grew in 0.1 M HEPES pH 7.5, 33% v/v PEG 400, identified from Morpheus MemGold2 sparse matrix screen. OXA-48, OXA-163 and OXA-405 crystals used for structure determination of nacubactam-bound complexes were grown in 0.1 M Tris pH 8.8 – 9.0, 20 – 50% PEG 400 at 10 °C, whilst avibactam-bound and unliganded structures of OXA-163 and OXA-405 were determined from crystals grown in 0.1 M Tris pH 8.5 – 9.0, 28 – 32% PEG 550 at 19 °C. Crystals were soaked with either 5 mM nacubactam or 15 – 100 mM avibactam and either cryoprotected with 20% glycerol before freezing, or frozen directly by immersion in liquid nitrogen. See <xref ref-type="supplementary-material" rid="SD1">Table S3</xref> for further details on crystallisation and ligand soaking experiments.</p><p id="P30">X-ray diffraction data were collected at beamline I03 of Diamond Light Source (Didcot, UK) or PROXIMA 2A beamline of SOLEIL (Paris, France) (see <xref ref-type="supplementary-material" rid="SD1">Table S2</xref> for X-ray collection and refinement statistics). Diffraction images were processed using the in-house Xia2 dials and Xia2 3dii pipelines, or merged via AIMLESS (CCP4), ensuring CC<sub>1/2</sub> greater than 0.3<sup><xref ref-type="bibr" rid="R41">41</xref>,<xref ref-type="bibr" rid="R42">42</xref></sup>. 5% of reflections in each dataset were reserved to calculate <italic>R</italic><sub>free</sub> values. Phases for uncomplexed structures were solved by molecular replacement in PhaserMR (Phenix) using an AlphaFold2 prediction as a search model<sup><xref ref-type="bibr" rid="R43">43</xref>,<xref ref-type="bibr" rid="R44">44</xref></sup>. Structures were then refined in phenix.refine using their respective uncomplexed structure (with waters removed) as a starting model for one round of rigid body fitting, followed by manual rebuilding and local refitting in Coot<sup><xref ref-type="bibr" rid="R45">45</xref>,<xref ref-type="bibr" rid="R46">46</xref></sup>. Ligands were fitted into active site <italic>F</italic><sub>o</sub>-<italic>F</italic><sub>c</sub> difference density with ligand geometry restraints generated by Grade2<sup><xref ref-type="bibr" rid="R47">47</xref></sup>. Figures of structures were generated in open-source PyMOL (Schrödinger)<sup><xref ref-type="bibr" rid="R48">48</xref></sup>.</p></sec><sec id="S12"><title>Enzyme kinetics</title><p id="P31">All enzyme kinetics experiments were performed in 50 mM HEPES pH 7.6, 50 mM NaPO<sub>4</sub> buffer supplemented with 50 mM NaHCO<sub>3</sub> and 50 µg.mL<sup>-1</sup> bovine serum albumin (BSA) in Greiner 96-well half area plates. Nitrocefin hydrolysis was determined with 1 nM enzyme, measuring changing absorbance at 486 nm over 10 mins (Δε 486 = 20,500 M<sup>-1</sup> cm<sup>-1</sup>) using a Clariostar plate reader (BMG LabTech)<sup><xref ref-type="bibr" rid="R49">49</xref></sup>. Steady-state parameters (<italic>K</italic><sub>M</sub>, <italic>k</italic><sub>cat</sub>) were calculated in Graphpad Prism v10.2 (<xref ref-type="supplementary-material" rid="SD1">Table S6</xref>). IC<sub>50</sub> values were determined as described in <sup><xref ref-type="bibr" rid="R16">16</xref></sup>, pre-incubating 1 nM enzyme with differing concentrations of inhibitor diluted in kinetics buffer for 10 minutes before adding 75 µM nitrocefin and measuring change in absorbance at 486 nm over 10 mins.</p></sec><sec id="S13"><title>Minimum inhibitory concentrations (MICs)</title><p id="P32">A gene encoding OXA-48 was cloned from pSU18 OXA-48<sup><xref ref-type="bibr" rid="R51">51</xref></sup> into an empty pUBYT vector<sup><xref ref-type="bibr" rid="R52">52</xref></sup>. OXA-163 and OXA-405 vectors were then generated from pUBYT OXA-48 using QuikChange Lightning site-directed mutagenesis kit (Agilent) (primers listed in <xref ref-type="supplementary-material" rid="SD1">Table S5</xref>). <italic>E. coli</italic> TOP10 (lab strain) and ATCC25922 (clinical reference strain) were transformed with their respective plasmids by heat shock. Differing concentrations of β-lactams were combined with 4 µg/mL avibactam (AVI) or nacubactam (NAC), dissolved in DMSO. MICs were determined by broth microdilution method using Mueller-Hinton broth (Sigma), following CLSI guidelines in 96-well microtiter plates (Corning)<sup><xref ref-type="bibr" rid="R53">53</xref></sup>. The microtiter plate was incubated for 16 – 20 hrs at 37 °C, and absorbance read on a Clariostar plate reader (BMG LabTech) at 600 nm.</p></sec><sec id="S14"><title>Molecular dynamics simulations</title><p id="P33">Extended molecular mechanics/molecular dynamics (MM MD) simulations (1.5 µs) were run for the uncomplexed, nacubactam- and avibactam-bound OXA-48, OXA-163 and OXA-405 structures. As a starting point for MM MD simulations a previously determined structure of OXA-48 bound to avibactam (PDB 4S2K<sup><xref ref-type="bibr" rid="R14">14</xref></sup>) was re-refined in phenix.refine<sup><xref ref-type="bibr" rid="R45">45</xref></sup> with a chloride ion added to the dimer interface following inspection of the <italic>F</italic><sub>o</sub>-<italic>F</italic><sub>c</sub> difference map, replacing the water originally modelled. As two dimers reside in the asymmetric unit of 4S2K, chains A and C were removed. Starting structures for simulations of uncomplexed and nacubactam-bound OXA-405 had sections of the β7 - α10 loop that were not modelled in the final crystal structure (residues 237-242) added using Fit Loop (by Rama Search) in Coot<sup><xref ref-type="bibr" rid="R46">46</xref></sup>. All starting models had crystallographic precipitant molecules removed, excepting the chloride ion found at the dimer interface of all enzyme structures. Amino acid protonation states were altered as predicted by PropKa, based on a system at pH 7.4<sup><xref ref-type="bibr" rid="R29">29</xref></sup>. Partial charges for avibactam, nacubactam and the carbamylated active site lysine were calculated using the R.E.D webserver<sup><xref ref-type="bibr" rid="R50">50</xref></sup>. Ligand forcefields were generated using General Amber Force Field (GAFF) parameters and the ff14SB MM forcefield was used for standard protein residues. Hydrogens were added to each complex by tleap (Amber20<sup><xref ref-type="bibr" rid="R51">51</xref></sup>) and systems solvated within a TIP3P water box<sup><xref ref-type="bibr" rid="R52">52</xref></sup> whose edges were at least 10 Å from any protein atoms, with sodium counterions added to balance the overall system charge. All non-water atoms were initially restrained (restraint weight of 100 kcal.mol<sup>-1</sup>.A<sup>-2</sup>) for water minimisation (100 cycles of steepest descent followed by 200 cycles of conjugate gradient), followed by minimisation of all hydrogen atoms, water molecules and chloride ions (1000 cycles of steepest descent, 2000 cycles of conjugate gradient). Systems were then heated to 298 K over 20 ps of simulation using a Langevin thermostat, and system pressure was equilibrated to 1.0 bar over 500 ps with a Berendsen barostat, restraining just the Cα atoms in both steps (restraint weights were 5 kcal.mol<sup>-1</sup>.A<sup>-2</sup>). Production simulations were run over 500 ns, repeating three times for a total sampling time of 1.5 µs for each complex. All simulation analyses were performed using CPPTRAJ<sup><xref ref-type="bibr" rid="R53">53</xref></sup>, with RMSD values calculated relative to the first deposited simulation structure (at 0.4 ns), excluding all hydrogen atoms and N-terminal residues up to and including Glu24 in both chains of the homodimer.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supplementary Information</label><caption><p id="P34">Sequences of oligonucleotide primers; conditions, data processing and validation statistics for crystallographic experiments; steady-state kinetic parameters for hydrolysis of reporter substrate (nitrocefin); supplementary images of crystal structures; analyses of molecular simulations (DOC)</p></caption><media xlink:href="EMS199779-supplement-Supplementary_Information.zip" mimetype="application" mime-subtype="zip" id="d2aAcEbC" position="anchor"/></supplementary-material></sec></body><back><ack id="S15"><title>Acknowledgements</title><p>All simulations were conducted using the facilities of the Advanced Computing Research Centre at the University of Bristol (<ext-link ext-link-type="uri" xlink:href="http://www.bris.ac.uk/acrc/">http://www.bris.ac.uk/acrc/</ext-link>). The authors thank Diamond Light Source (beamline I03, proposals 23269 and 31440) and the SOLEIL synchrotron (beamline PROXIMA 2A), and the respective beamline scientists for their support collecting the X-ray diffraction data presented here. K.E.G., J.S. and C.J.S. acknowledge funding from the U.K. Biotechnology and Biological Sciences Research Council (BBSRC, BB/W001187/1). M.B. was supported by the BBSRC-funded South West Biosciences Doctoral Training Partnership (BB/T008741/10). This work was supported in part by grant MR/W006308/1 for the GW4 BIOMED2 DTP, awarded to the Universities of Bath, Bristol, Cardiff and Exeter from the Medical Research Council (MRC)/UKRI. C.L.T., J.S. and A.J.M. thank the Medical Research Council for support through the grant MR/T016035/1. This work is part of a project that has received funding from the European Research Council under the European Horizon 2020 research and innovation program (PREDACTED Advanced Grant Agreement no. 101021207) to A.J.M. and J.S.</p></ack><sec id="S18" sec-type="data-availability"><title>Data availability statement</title><p id="P35">Structure factors and coordinates for all crystal structures presented here have been deposited with the Protein Data Bank (PDB) with the following accession numbers: uncomplexed OXA-48 (9H11), OXA-48 in complex with nacubactam (9H12), uncomplexed OXA-163 (9H13), OXA-163 in complex with avibactam (9H14), OXA-163 in complex with nacubactam (9H15), uncomplexed OXA-405 (9H16), OXA-405 in complex with avibactam (9H17), OXA-405 in complex with nacubactam (9H18). All raw MD simulations data (including equilibrium and non-equilibrium simulations) will be made freely available at the University of Bristol Research Data Repository (<ext-link ext-link-type="uri" xlink:href="https://data.bris.ac.uk/">https://data.bris.ac.uk/</ext-link>). Analysis scripts will be made available upon request.</p></sec><glossary><title>Abbreviations</title><def-list><def-item><term>BLI</term><def><p>β-lactamase inhibitor</p></def></def-item><def-item><term>DBO</term><def><p>diazabicyclooctane</p></def></def-item><def-item><term>MM MD</term><def><p>molecular mechanics molecular dynamics</p></def></def-item><def-item><term>OXA</term><def><p>oxacillinase</p></def></def-item><def-item><term>RMSD</term><def><p>root mean-squared deviation</p></def></def-item><def-item><term>RMSF</term><def><p>root mean-squared fluctuation</p></def></def-item><def-item><term>SBL</term><def><p>serine β-lactamase</p></def></def-item></def-list></glossary><fn-group><fn id="FN1" fn-type="con"><p id="P36"><bold><underline>Author Contributions</underline></bold></p><p id="P37">J.F.H., K.E.G., C.J.S. and J.S. conceived the experiments. J.F.H. and K.E.G. performed laboratory experiments and crystallographic data collection/processing, with supervision from C.L.T., P.H, J.M.S and Y.T. J.F.H. undertook molecular simulations with training and supervision from M.B. J.F.H. and K.E.G. drafted the manuscript, with revisions by J.S. and input from and final approval by all authors.</p></fn></fn-group><ref-list><ref id="R1"><label>(1)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Naghavi</surname><given-names>M</given-names></name><name><surname>Vollset</surname><given-names>SE</given-names></name><name><surname>Ikuta</surname><given-names>KS</given-names></name><name><surname>Swetschinski</surname><given-names>LR</given-names></name><name><surname>Gray</surname><given-names>AP</given-names></name><name><surname>Wool</surname><given-names>EE</given-names></name><name><surname>Aguilar</surname><given-names>GR</given-names></name><name><surname>Mestrovic</surname><given-names>T</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Hsu</surname><given-names>RL</given-names></name><etal/></person-group><article-title>Global Burden of Bacterial Antimicrobial Resistance 1990–2021: A Systematic Analysis with Forecasts to 2050</article-title><source>The Lancet</source><year>2024</year><comment>0 (0)</comment><pub-id pub-id-type="pmid">39299261</pub-id></element-citation></ref><ref id="R2"><label>(2)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bush</surname><given-names>K</given-names></name><name><surname>Bradford</surname><given-names>PA</given-names></name></person-group><article-title>β-Lactams and β-Lactamase Inhibitors: An Overview</article-title><source>Cold Spring Harb Perspect Med</source><year>2016</year><volume>6</volume><issue>8</issue><elocation-id>a025247</elocation-id><pub-id pub-id-type="pmcid">PMC4968164</pub-id><pub-id pub-id-type="pmid">27329032</pub-id><pub-id pub-id-type="doi">10.1101/cshperspect.a025247</pub-id></element-citation></ref><ref id="R3"><label>(3)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Versporten</surname><given-names>A</given-names></name><name><surname>Zarb</surname><given-names>P</given-names></name><name><surname>Caniaux</surname><given-names>I</given-names></name><name><surname>Gros</surname><given-names>M-F</given-names></name><name><surname>Drapier</surname><given-names>N</given-names></name><name><surname>Miller</surname><given-names>M</given-names></name><name><surname>Jarlier</surname><given-names>V</given-names></name><name><surname>Nathwani</surname><given-names>D</given-names></name><name><surname>Goossens</surname><given-names>H</given-names></name><name><surname>Koraqi</surname><given-names>A</given-names></name><name><surname>Hoxha</surname><given-names>I</given-names></name><etal/></person-group><article-title>Antimicrobial Consumption and Resistance in Adult Hospital Inpatients in 53 Countries: Results of an Internet-Based Global Point Prevalence Survey</article-title><source>The Lancet Global Health</source><year>2018</year><volume>6</volume><issue>6</issue><fpage>e619</fpage><lpage>e629</lpage><pub-id pub-id-type="pmid">29681513</pub-id></element-citation></ref><ref id="R4"><label>(4)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tooke</surname><given-names>CL</given-names></name><name><surname>Hinchliffe</surname><given-names>P</given-names></name><name><surname>Bragginton</surname><given-names>EC</given-names></name><name><surname>Colenso</surname><given-names>CK</given-names></name><name><surname>Hirvonen</surname><given-names>VHA</given-names></name><name><surname>Takebayashi</surname><given-names>Y</given-names></name><name><surname>Spencer</surname><given-names>J</given-names></name></person-group><article-title>β-Lactamases and β-Lactamase Inhibitors in the 21st Century</article-title><source>Journal of Molecular Biology</source><year>2019</year><volume>431</volume><issue>18</issue><fpage>3472</fpage><lpage>3500</lpage><pub-id pub-id-type="pmcid">PMC6723624</pub-id><pub-id pub-id-type="pmid">30959050</pub-id><pub-id pub-id-type="doi">10.1016/j.jmb.2019.04.002</pub-id></element-citation></ref><ref id="R5"><label>(5)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ambler</surname><given-names>RP</given-names></name></person-group><article-title>The Structure of Beta-Lactamases</article-title><source>Philos Trans R Soc Lond B Biol Sci</source><year>1980</year><volume>289</volume><issue>1036</issue><fpage>321</fpage><lpage>331</lpage><pub-id pub-id-type="pmid">6109327</pub-id></element-citation></ref><ref id="R6"><label>(6)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hirvonen</surname><given-names>VHA</given-names></name><name><surname>Spencer</surname><given-names>J</given-names></name><name><surname>van der Kamp</surname><given-names>MW</given-names></name></person-group><article-title>Antimicrobial Resistance Conferred by OXA-48 β-Lactamases: Towards a Detailed Mechanistic Understanding</article-title><source>Antimicrobial Agents and Chemotherapy</source><year>2021</year><volume>65</volume><issue>6</issue><pub-id pub-id-type="pmcid">PMC8316048</pub-id><pub-id pub-id-type="pmid">33753332</pub-id><pub-id pub-id-type="doi">10.1128/AAC.00184-21</pub-id></element-citation></ref><ref id="R7"><label>(7)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murray</surname><given-names>CJL</given-names></name><name><surname>Ikuta</surname><given-names>KS</given-names></name><name><surname>Sharara</surname><given-names>F</given-names></name><name><surname>Swetschinski</surname><given-names>L</given-names></name><name><surname>Aguilar</surname><given-names>GR</given-names></name><name><surname>Gray</surname><given-names>A</given-names></name><name><surname>Han</surname><given-names>C</given-names></name><name><surname>Bisignano</surname><given-names>C</given-names></name><name><surname>Rao</surname><given-names>P</given-names></name><name><surname>Wool</surname><given-names>E</given-names></name><name><surname>Johnson</surname><given-names>SC</given-names></name><etal/></person-group><article-title>Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis</article-title><source>The Lancet</source><year>2022</year><volume>399</volume><issue>10325</issue><fpage>629</fpage><lpage>655</lpage><pub-id pub-id-type="pmcid">PMC8841637</pub-id><pub-id pub-id-type="pmid">35065702</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(21)02724-0</pub-id></element-citation></ref><ref id="R8"><label>(8)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitout</surname><given-names>JDD</given-names></name><name><surname>Peirano</surname><given-names>G</given-names></name><name><surname>Kock</surname><given-names>MM</given-names></name><name><surname>Strydom</surname><given-names>K-A</given-names></name><name><surname>Matsumura</surname><given-names>Y</given-names></name></person-group><article-title>The Global Ascendency of OXA-48-Type Carbapenemases</article-title><source>Clin Microbiol Rev</source><year>2019</year><volume>33</volume><issue>1</issue><elocation-id>e00102-19</elocation-id><pub-id pub-id-type="pmcid">PMC6860007</pub-id><pub-id pub-id-type="pmid">31722889</pub-id><pub-id pub-id-type="doi">10.1128/CMR.00102-19</pub-id></element-citation></ref><ref id="R9"><label>(9)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordmann</surname><given-names>P</given-names></name><name><surname>Dortet</surname><given-names>L</given-names></name><name><surname>Poirel</surname><given-names>L</given-names></name></person-group><article-title>Carbapenem Resistance in Enterobacteriaceae: Here Is the Storm!</article-title><source>Trends Mol Med</source><year>2012</year><volume>18</volume><issue>5</issue><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="pmid">22480775</pub-id></element-citation></ref><ref id="R10"><label>(10)</label><element-citation publication-type="book"><source>WHO Bacterial Priority Pathogens List, 2024: Bacterial Pathogens of Public Health Importance to Guide Research, Development and Strategies to Prevent and Control Antimicrobial Resistance</source><publisher-name>World Health Organization</publisher-name><year>2024</year><date-in-citation>accessed 2024-10-24</date-in-citation><comment><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/i/item/9789240093461">https://www.who.int/publications/i/item/9789240093461</ext-link></comment></element-citation></ref><ref id="R11"><label>(11)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fröhlich</surname><given-names>C</given-names></name><name><surname>Sørum</surname><given-names>V</given-names></name><name><surname>Thomassen</surname><given-names>AM</given-names></name><name><surname>Johnsen</surname><given-names>PJ</given-names></name><name><surname>Leiros</surname><given-names>H-KS</given-names></name><name><surname>Samuelsen</surname><given-names>Ø</given-names></name></person-group><article-title>OXA-48-Mediated Ceftazidime-Avibactam Resistance Is Associated with Evolutionary Trade-Offs</article-title><source>mSphere</source><year>2019</year><volume>4</volume><issue>2</issue><pub-id pub-id-type="pmcid">PMC6437269</pub-id><pub-id pub-id-type="pmid">30918055</pub-id><pub-id pub-id-type="doi">10.1128/mSphere.00024-19</pub-id></element-citation></ref><ref id="R12"><label>(12)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thakkur</surname><given-names>V</given-names></name><name><surname>Das</surname><given-names>CK</given-names></name><name><surname>Nair</surname><given-names>NN</given-names></name></person-group><article-title>Inhibition Mechanism of Class D β-Lactamases by Avibactam</article-title><source>ACS Catal</source><year>2022</year><volume>12</volume><issue>16</issue><fpage>10338</fpage><lpage>10352</lpage><pub-id pub-id-type="doi">10.1021/acscatal.2c02693</pub-id></element-citation></ref><ref id="R13"><label>(13)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ehmann</surname><given-names>DE</given-names></name><name><surname>Jahić</surname><given-names>H</given-names></name><name><surname>Ross</surname><given-names>PL</given-names></name><name><surname>Gu</surname><given-names>R-F</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Kern</surname><given-names>G</given-names></name><name><surname>Walkup</surname><given-names>GK</given-names></name><name><surname>Fisher</surname><given-names>SL</given-names></name></person-group><article-title>Avibactam Is a Covalent, Reversible, Non–β-Lactam β-Lactamase Inhibitor</article-title><source>Proceedings of the National Academy of Sciences</source><year>2012</year><volume>109</volume><issue>29</issue><fpage>11663</fpage><lpage>11668</lpage><pub-id pub-id-type="pmcid">PMC3406822</pub-id><pub-id pub-id-type="pmid">22753474</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1205073109</pub-id></element-citation></ref><ref id="R14"><label>(14)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>DT</given-names></name><name><surname>King</surname><given-names>AM</given-names></name><name><surname>Lal</surname><given-names>SM</given-names></name><name><surname>Wright</surname><given-names>GD</given-names></name><name><surname>Strynadka</surname><given-names>NCJ</given-names></name></person-group><article-title>Molecular Mechanism of Avibactam-Mediated β-Lactamase Inhibition</article-title><source>ACS Infect Dis</source><year>2015</year><volume>1</volume><issue>4</issue><fpage>175</fpage><lpage>184</lpage><pub-id pub-id-type="pmid">27622530</pub-id></element-citation></ref><ref id="R15"><label>(15)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahiri</surname><given-names>SD</given-names></name><name><surname>Mangani</surname><given-names>S</given-names></name><name><surname>Jahić</surname><given-names>H</given-names></name><name><surname>Benvenuti</surname><given-names>M</given-names></name><name><surname>Durand-Reville</surname><given-names>TF</given-names></name><name><surname>De Luca</surname><given-names>F</given-names></name><name><surname>Ehmann</surname><given-names>DE</given-names></name><name><surname>Rossolini</surname><given-names>GM</given-names></name><name><surname>Alm</surname><given-names>RA</given-names></name><name><surname>Docquier</surname><given-names>J-D</given-names></name></person-group><article-title>Molecular Basis of Selective Inhibition and Slow Reversibility of Avibactam against Class D Carbapenemases: A Structure-Guided Study of OXA-24 and OXA-48</article-title><source>ACS Chem Biol</source><year>2015</year><volume>10</volume><issue>2</issue><fpage>591</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">25406838</pub-id></element-citation></ref><ref id="R16"><label>(16)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tooke</surname><given-names>CL</given-names></name><name><surname>Hinchliffe</surname><given-names>P</given-names></name><name><surname>Lang</surname><given-names>PA</given-names></name><name><surname>Mulholland</surname><given-names>AJ</given-names></name><name><surname>Brem</surname><given-names>J</given-names></name><name><surname>Schofield</surname><given-names>CJ</given-names></name><name><surname>Spencer</surname><given-names>J</given-names></name></person-group><article-title>Molecular Basis of Class A β-Lactamase Inhibition by Relebactam</article-title><source>Antimicrobial Agents and Chemotherapy</source><year>2019</year><volume>63</volume><issue>10</issue><pub-id pub-id-type="pmcid">PMC6761529</pub-id><pub-id pub-id-type="pmid">31383664</pub-id><pub-id pub-id-type="doi">10.1128/AAC.00564-19</pub-id></element-citation></ref><ref id="R17"><label>(17)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>A</given-names></name><name><surname>Harris</surname><given-names>P</given-names></name><name><surname>Henderson</surname><given-names>A</given-names></name><name><surname>Paterson</surname><given-names>D</given-names></name></person-group><article-title>Treatment of Infections by OXA-48-Producing Enterobacteriaceae</article-title><source>Antimicrobial Agents and Chemotherapy</source><year>2018</year><volume>62</volume><issue>11</issue><pub-id pub-id-type="pmcid">PMC6201068</pub-id><pub-id pub-id-type="pmid">30104282</pub-id><pub-id pub-id-type="doi">10.1128/AAC.01195-18</pub-id></element-citation></ref><ref id="R18"><label>(18)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Catalán</surname><given-names>P</given-names></name><name><surname>Bell</surname><given-names>H</given-names></name><name><surname>Baumann</surname><given-names>P</given-names></name><name><surname>Cooke</surname><given-names>R</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zappalà</surname><given-names>D</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Blackburn</surname><given-names>GM</given-names></name><etal/></person-group><article-title>An Ion-Pair Induced Intermediate Complex Captured in Class D Carbapenemase Reveals Chloride Ion as a Janus Effector Modulating Activity</article-title><source>ACS Cent Sci</source><year>2023</year><volume>9</volume><issue>12</issue><fpage>2339</fpage><lpage>2349</lpage><pub-id pub-id-type="pmcid">PMC10755735</pub-id><pub-id pub-id-type="pmid">38161376</pub-id><pub-id pub-id-type="doi">10.1021/acscentsci.3c00609</pub-id></element-citation></ref><ref id="R19"><label>(19)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Papp-Wallace</surname><given-names>KM</given-names></name><name><surname>Nguyen</surname><given-names>NQ</given-names></name><name><surname>Jacobs</surname><given-names>MR</given-names></name><name><surname>Bethel</surname><given-names>CR</given-names></name><name><surname>Barnes</surname><given-names>MD</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Bajaksouzian</surname><given-names>S</given-names></name><name><surname>Rudin</surname><given-names>SD</given-names></name><name><surname>Rather</surname><given-names>PN</given-names></name><name><surname>Bhavsar</surname><given-names>S</given-names></name><name><surname>Ravikumar</surname><given-names>T</given-names></name><etal/></person-group><article-title>Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using β-Lactamase Inhibitors and β-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234</article-title><source>J Med Chem</source><year>2018</year><volume>61</volume><issue>9</issue><fpage>4067</fpage><lpage>4086</lpage><pub-id pub-id-type="pmcid">PMC6131718</pub-id><pub-id pub-id-type="pmid">29627985</pub-id><pub-id pub-id-type="doi">10.1021/acs.jmedchem.8b00091</pub-id></element-citation></ref><ref id="R20"><label>(20)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>DT</given-names></name><name><surname>Leiris</surname><given-names>S</given-names></name><name><surname>Zalacain</surname><given-names>M</given-names></name><name><surname>Sprynski</surname><given-names>N</given-names></name><name><surname>Castandet</surname><given-names>J</given-names></name><name><surname>Bousquet</surname><given-names>J</given-names></name><name><surname>Lozano</surname><given-names>C</given-names></name><name><surname>Llanos</surname><given-names>A</given-names></name><name><surname>Alibaud</surname><given-names>L</given-names></name><name><surname>Vasa</surname><given-names>S</given-names></name><name><surname>Pattipati</surname><given-names>R</given-names></name><etal/></person-group><article-title>Discovery of ANT3310, a Novel Broad-Spectrum Serine β-Lactamase Inhibitor of the Diazabicyclooctane Class, Which Strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter Baumannii</article-title><source>J Med Chem</source><year>2020</year><volume>63</volume><issue>24</issue><fpage>15802</fpage><lpage>15820</lpage><pub-id pub-id-type="pmid">33306385</pub-id></element-citation></ref><ref id="R21"><label>(21)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blizzard</surname><given-names>TA</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Bodner</surname><given-names>R</given-names></name><name><surname>Gude</surname><given-names>C</given-names></name><name><surname>Imbriglio</surname><given-names>J</given-names></name><name><surname>Young</surname><given-names>K</given-names></name><name><surname>Park</surname><given-names>Y-W</given-names></name><name><surname>Ogawa</surname><given-names>A</given-names></name><name><surname>Raghoobar</surname><given-names>S</given-names></name><etal/></person-group><article-title>Discovery of MK-7655, a β-Lactamase Inhibitor for Combination with Primaxin®</article-title><source>Bioorganic &amp; Medicinal Chemistry Letters</source><year>2014</year><volume>24</volume><issue>3</issue><fpage>780</fpage><lpage>785</lpage><pub-id pub-id-type="pmid">24433862</pub-id></element-citation></ref><ref id="R22"><label>(22)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morinaka</surname><given-names>A</given-names></name><name><surname>Tsutsumi</surname><given-names>Y</given-names></name><name><surname>Yamada</surname><given-names>M</given-names></name><name><surname>Suzuki</surname><given-names>K</given-names></name><name><surname>Watanabe</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Furuuchi</surname><given-names>T</given-names></name><name><surname>Inamura</surname><given-names>S</given-names></name><name><surname>Sakamaki</surname><given-names>Y</given-names></name><name><surname>Mitsuhashi</surname><given-names>N</given-names></name><name><surname>Ida</surname><given-names>T</given-names></name><etal/></person-group><article-title>OP0595, a New Diazabicyclooctane: Mode of Action as a Serine β-Lactamase Inhibitor, Antibiotic and β-Lactam ‘Enhancer’</article-title><source>Journal of Antimicrobial Chemotherapy</source><year>2015</year><volume>70</volume><issue>10</issue><fpage>2779</fpage><lpage>2786</lpage><pub-id pub-id-type="pmid">26089439</pub-id></element-citation></ref><ref id="R23"><label>(23)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poirel</surname><given-names>L</given-names></name><name><surname>Castanheira</surname><given-names>M</given-names></name><name><surname>Carrër</surname><given-names>A</given-names></name><name><surname>Rodriguez</surname><given-names>CP</given-names></name><name><surname>Jones</surname><given-names>RN</given-names></name><name><surname>Smayevsky</surname><given-names>J</given-names></name><name><surname>Nordmann</surname><given-names>P</given-names></name></person-group><article-title>OXA-163, an OXA-48-Related Class D β-Lactamase with Extended Activity Toward Expanded-Spectrum Cephalosporins</article-title><source>Antimicrobial Agents and Chemotherapy</source><year>2011</year><volume>55</volume><issue>6</issue><fpage>2546</fpage><lpage>2551</lpage><pub-id pub-id-type="pmcid">PMC3101449</pub-id><pub-id pub-id-type="pmid">21422200</pub-id><pub-id pub-id-type="doi">10.1128/AAC.00022-11</pub-id></element-citation></ref><ref id="R24"><label>(24)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oueslati</surname><given-names>S</given-names></name><name><surname>Retailleau</surname><given-names>P</given-names></name><name><surname>Marchini</surname><given-names>L</given-names></name><name><surname>Dortet</surname><given-names>L</given-names></name><name><surname>Bonnin</surname><given-names>RA</given-names></name><name><surname>Iorga</surname><given-names>BI</given-names></name><name><surname>Naas</surname><given-names>T</given-names></name></person-group><article-title>Biochemical and Structural Characterization of OXA-405, an OXA-48 Variant with Extended-Spectrum β-Lactamase Activity</article-title><source>Microorganisms</source><year>2019</year><volume>8</volume><issue>1</issue><fpage>24</fpage><pub-id pub-id-type="pmcid">PMC7022249</pub-id><pub-id pub-id-type="pmid">31877796</pub-id><pub-id pub-id-type="doi">10.3390/microorganisms8010024</pub-id></element-citation></ref><ref id="R25"><label>(25)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dortet</surname><given-names>L</given-names></name><name><surname>Oueslati</surname><given-names>S</given-names></name><name><surname>Jeannot</surname><given-names>K</given-names></name><name><surname>Tandé</surname><given-names>D</given-names></name><name><surname>Naas</surname><given-names>T</given-names></name><name><surname>Nordmann</surname><given-names>P</given-names></name></person-group><article-title>Genetic and Biochemical Characterization of OXA-405, an OXA-48-Type Extended-Spectrum β-Lactamase without Significant Carbapenemase Activity</article-title><source>Antimicrobial Agents and Chemotherapy</source><year>2015</year><volume>59</volume><issue>7</issue><fpage>3823</fpage><lpage>3828</lpage><pub-id pub-id-type="pmcid">PMC4468662</pub-id><pub-id pub-id-type="pmid">25870062</pub-id><pub-id pub-id-type="doi">10.1128/AAC.05058-14</pub-id></element-citation></ref><ref id="R26"><label>(26)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>BA</given-names></name><name><surname>Thomassen</surname><given-names>AM</given-names></name><name><surname>Nesheim</surname><given-names>BHB</given-names></name><name><surname>Carlsen</surname><given-names>TJO</given-names></name><name><surname>Isaksson</surname><given-names>J</given-names></name><name><surname>Christopeit</surname><given-names>T</given-names></name><name><surname>Leiros</surname><given-names>H-KS</given-names></name></person-group><article-title>The Biological Assembly of OXA-48 Reveals a Dimer Interface with High Charge Complementarity and Very High Affinity</article-title><source>The FEBS Journal</source><year>2018</year><volume>285</volume><issue>22</issue><fpage>4214</fpage><lpage>4228</lpage><pub-id pub-id-type="pmid">30153368</pub-id></element-citation></ref><ref id="R27"><label>(27)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>NK</given-names></name><name><surname>Toth</surname><given-names>M</given-names></name><name><surname>Stasyuk</surname><given-names>A</given-names></name><name><surname>Vakulenko</surname><given-names>SB</given-names></name><name><surname>Smith</surname><given-names>CA</given-names></name></person-group><article-title>In Crystallo Time-Resolved Interaction of the Clostridioides Difficile CDD-1 Enzyme with Avibactam Provides New Insights into the Catalytic Mechanism of Class D β-Lactamases</article-title><source>ACS Infect Dis</source><year>2021</year><volume>7</volume><issue>6</issue><fpage>1765</fpage><lpage>1776</lpage><pub-id pub-id-type="pmcid">PMC8808381</pub-id><pub-id pub-id-type="pmid">33908775</pub-id><pub-id pub-id-type="doi">10.1021/acsinfecdis.1c00094</pub-id></element-citation></ref><ref id="R28"><label>(28)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>CA</given-names></name><name><surname>Stewart</surname><given-names>NK</given-names></name><name><surname>Toth</surname><given-names>M</given-names></name><name><surname>Vakulenko</surname><given-names>SB</given-names></name></person-group><article-title>Structural Insights into the Mechanism of Carbapenemase Activity of the OXA-48 β-Lactamase</article-title><source>Antimicrob Agents Chemother</source><year>2019</year><volume>63</volume><issue>10</issue><elocation-id>e01202-19</elocation-id><pub-id pub-id-type="pmcid">PMC6761500</pub-id><pub-id pub-id-type="pmid">31358584</pub-id><pub-id pub-id-type="doi">10.1128/AAC.01202-19</pub-id></element-citation></ref><ref id="R29"><label>(29)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Robertson</surname><given-names>AD</given-names></name><name><surname>Jensen</surname><given-names>JH</given-names></name></person-group><article-title>Very Fast Empirical Prediction and Rationalization of Protein pKa Values</article-title><source>Proteins: Structure, Function, and Bioinformatics</source><year>2005</year><volume>61</volume><issue>4</issue><fpage>704</fpage><lpage>721</lpage><pub-id pub-id-type="pmid">16231289</pub-id></element-citation></ref><ref id="R30"><label>(30)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anstine</surname><given-names>D</given-names></name><name><surname>Zubatyuk</surname><given-names>R</given-names></name><name><surname>Isayev</surname><given-names>O</given-names></name></person-group><article-title>AIMNet2: A Neural Network Potential to Meet Your Neutral, Charged, Organic, and Elemental-Organic Needs</article-title><source>ChemRxiv</source><year>2023</year><month>October</month><day>12</day><pub-id pub-id-type="doi">10.26434/chemrxiv-2023-296ch</pub-id></element-citation></ref><ref id="R31"><label>(31)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pan</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>JZH</given-names></name><name><surname>Ji</surname><given-names>C</given-names></name></person-group><article-title>MolGpka: A Web Server for Small Molecule pKa Prediction Using a Graph-Convolutional Neural Network</article-title><source>J Chem Inf Model</source><year>2021</year><volume>61</volume><issue>7</issue><fpage>3159</fpage><lpage>3165</lpage><pub-id pub-id-type="pmid">34251213</pub-id></element-citation></ref><ref id="R32"><label>(32)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>King</surname><given-names>AM</given-names></name><name><surname>King</surname><given-names>DT</given-names></name><name><surname>French</surname><given-names>S</given-names></name><name><surname>Brouillette</surname><given-names>E</given-names></name><name><surname>Asli</surname><given-names>A</given-names></name><name><surname>Alexander</surname><given-names>JAN</given-names></name><name><surname>Vuckovic</surname><given-names>M</given-names></name><name><surname>Maiti</surname><given-names>SN</given-names></name><name><surname>Parr</surname><given-names>TR</given-names><suffix>Jr</suffix></name><name><surname>Brown</surname><given-names>ED</given-names></name><name><surname>Malouin</surname><given-names>F</given-names></name><etal/></person-group><article-title>Structural and Kinetic Characterization of Diazabicyclooctanes as Dual Inhibitors of Both Serine-β-Lactamases and Penicillin-Binding Proteins</article-title><source>ACS Chem Biol</source><year>2016</year><volume>11</volume><issue>4</issue><fpage>864</fpage><lpage>868</lpage><pub-id pub-id-type="pmid">26731698</pub-id></element-citation></ref><ref id="R33"><label>(33)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moya</surname><given-names>B</given-names></name><name><surname>Barcelo</surname><given-names>IM</given-names></name><name><surname>Bhagwat</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name><name><surname>Bou</surname><given-names>G</given-names></name><name><surname>Papp-Wallace</surname><given-names>KM</given-names></name><name><surname>Bonomo</surname><given-names>RA</given-names></name><name><surname>Oliver</surname><given-names>A</given-names></name></person-group><article-title>WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent “β-Lactam Enhancer” Activity against Pseudomonas Aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones</article-title><source>Antimicrobial Agents and Chemotherapy</source><year>2017</year><volume>61</volume><issue>6</issue><pub-id pub-id-type="pmcid">PMC5444176</pub-id><pub-id pub-id-type="pmid">28289035</pub-id><pub-id pub-id-type="doi">10.1128/AAC.02529-16</pub-id></element-citation></ref><ref id="R34"><label>(34)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Che</surname><given-names>T</given-names></name><name><surname>Bonomo</surname><given-names>RA</given-names></name><name><surname>Shanmugam</surname><given-names>S</given-names></name><name><surname>Bethel</surname><given-names>CR</given-names></name><name><surname>Pusztai-Carey</surname><given-names>M</given-names></name><name><surname>Buynak</surname><given-names>JD</given-names></name><name><surname>Carey</surname><given-names>PR</given-names></name></person-group><article-title>Carboxylation and Decarboxylation of Active Site Lys 84 Controls the Activity of OXA-24 β-Lactamase of Acinetobacter Baumannii: Raman Crystallographic and Solution Evidence</article-title><source>J Am Chem Soc</source><year>2012</year><volume>134</volume><issue>27</issue><fpage>11206</fpage><lpage>11215</lpage><pub-id pub-id-type="pmcid">PMC3404726</pub-id><pub-id pub-id-type="pmid">22702961</pub-id><pub-id pub-id-type="doi">10.1021/ja303168n</pub-id></element-citation></ref><ref id="R35"><label>(35)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golemi</surname><given-names>D</given-names></name><name><surname>Maveyraud</surname><given-names>L</given-names></name><name><surname>Vakulenko</surname><given-names>S</given-names></name><name><surname>Samama</surname><given-names>J-P</given-names></name><name><surname>Mobashery</surname><given-names>S</given-names></name></person-group><article-title>Critical Involvement of a Carbamylated Lysine in Catalytic Function of Class D β-Lactamases</article-title><source>Proceedings of the National Academy of Sciences</source><year>2001</year><volume>98</volume><issue>25</issue><fpage>14280</fpage><lpage>14285</lpage><pub-id pub-id-type="pmcid">PMC64673</pub-id><pub-id pub-id-type="pmid">11724923</pub-id><pub-id pub-id-type="doi">10.1073/pnas.241442898</pub-id></element-citation></ref><ref id="R36"><label>(36)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Cross</surname><given-names>JB</given-names></name><name><surname>Vreven</surname><given-names>T</given-names></name><name><surname>Meroueh</surname><given-names>SO</given-names></name><name><surname>Mobashery</surname><given-names>S</given-names></name><name><surname>Schlegel</surname><given-names>HB</given-names></name></person-group><article-title>Lysine Carboxylation in Proteins: OXA-10 B-lactamase</article-title><source>Proteins</source><year>2005</year><volume>61</volume><issue>2</issue><fpage>246</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">16121396</pub-id></element-citation></ref><ref id="R37"><label>(37)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berrow</surname><given-names>NS</given-names></name><name><surname>Alderton</surname><given-names>D</given-names></name><name><surname>Sainsbury</surname><given-names>S</given-names></name><name><surname>Nettleship</surname><given-names>J</given-names></name><name><surname>Assenberg</surname><given-names>R</given-names></name><name><surname>Rahman</surname><given-names>N</given-names></name><name><surname>Stuart</surname><given-names>DI</given-names></name><name><surname>Owens</surname><given-names>RJ</given-names></name></person-group><article-title>A Versatile Ligation-Independent Cloning Method Suitable for High-Throughput Expression Screening Applications</article-title><source>Nucleic Acids Research</source><year>2007</year><volume>35</volume><issue>6</issue><fpage>e45</fpage><pub-id pub-id-type="pmcid">PMC1874605</pub-id><pub-id pub-id-type="pmid">17317681</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkm047</pub-id></element-citation></ref><ref id="R38"><label>(38)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cahill</surname><given-names>ST</given-names></name><name><surname>Cain</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>DY</given-names></name><name><surname>Lohans</surname><given-names>CT</given-names></name><name><surname>Wareham</surname><given-names>DW</given-names></name><name><surname>Oswin</surname><given-names>HP</given-names></name><name><surname>Mohammed</surname><given-names>J</given-names></name><name><surname>Spencer</surname><given-names>J</given-names></name><name><surname>Fishwick</surname><given-names>CWG</given-names></name><name><surname>McDonough</surname><given-names>MA</given-names></name><name><surname>Schofield</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Cyclic Boronates Inhibit All Classes of β-Lactamases</article-title><source>Antimicrobial Agents and Chemotherapy</source><year>2017</year><volume>61</volume><issue>4</issue><pub-id pub-id-type="pmcid">PMC5365654</pub-id><pub-id pub-id-type="pmid">28115348</pub-id><pub-id pub-id-type="doi">10.1128/AAC.02260-16</pub-id></element-citation></ref><ref id="R39"><label>(39)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laemmli</surname><given-names>UK</given-names></name></person-group><article-title>Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4</article-title><source>Nature</source><year>1970</year><volume>227</volume><issue>5259</issue><fpage>680</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">5432063</pub-id></element-citation></ref><ref id="R40"><label>(40)</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gasteiger</surname><given-names>E</given-names></name><name><surname>Hoogland</surname><given-names>C</given-names></name><name><surname>Gattiker</surname><given-names>A</given-names></name><name><surname>Duvaud</surname><given-names>S</given-names></name><name><surname>Wilkins</surname><given-names>MR</given-names></name><name><surname>Appel</surname><given-names>RD</given-names></name><name><surname>Bairoch</surname><given-names>A</given-names></name></person-group><chapter-title>Protein Identification and Analysis Tools on the Expasy Server</chapter-title><source>The Proteomics Protocols Handbook</source><publisher-name>Humana Press</publisher-name><year>2005</year><fpage>571</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">10027275</pub-id></element-citation></ref><ref id="R41"><label>(41)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Winter</surname><given-names>G</given-names></name></person-group><article-title>Xia2: An Expert System for Macromolecular Crystallography Data Reduction</article-title><source>J Appl Cryst</source><year>2010</year><volume>43</volume><issue>1</issue><fpage>186</fpage><lpage>190</lpage><pub-id pub-id-type="doi">10.1107/S0021889809045701</pub-id></element-citation></ref><ref id="R42"><label>(42)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname><given-names>PR</given-names></name><name><surname>Murshudov</surname><given-names>GN</given-names></name></person-group><article-title>How Good Are My Data and What Is the Resolution?</article-title><source>Acta Crystallogr D Biol Crystallogr</source><year>2013</year><volume>69</volume><issue>Pt 7</issue><fpage>1204</fpage><lpage>1214</lpage><pub-id pub-id-type="pmcid">PMC3689523</pub-id><pub-id pub-id-type="pmid">23793146</pub-id><pub-id pub-id-type="doi">10.1107/S0907444913000061</pub-id></element-citation></ref><ref id="R43"><label>(43)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jumper</surname><given-names>J</given-names></name><name><surname>Evans</surname><given-names>R</given-names></name><name><surname>Pritzel</surname><given-names>A</given-names></name><name><surname>Green</surname><given-names>T</given-names></name><name><surname>Figurnov</surname><given-names>M</given-names></name><name><surname>Ronneberger</surname><given-names>O</given-names></name><name><surname>Tunyasuvunakool</surname><given-names>K</given-names></name><name><surname>Bates</surname><given-names>R</given-names></name><name><surname>Žídek</surname><given-names>A</given-names></name><name><surname>Potapenko</surname><given-names>A</given-names></name><name><surname>Bridgland</surname><given-names>A</given-names></name><etal/></person-group><article-title>Highly Accurate Protein Structure Prediction with AlphaFold</article-title><source>Nature</source><year>2021</year><volume>596</volume><issue>7873</issue><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="pmcid">PMC8371605</pub-id><pub-id pub-id-type="pmid">34265844</pub-id><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id></element-citation></ref><ref id="R44"><label>(44)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>AJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Winn</surname><given-names>MD</given-names></name><name><surname>Storoni</surname><given-names>LC</given-names></name><name><surname>Read</surname><given-names>RJ</given-names></name></person-group><article-title>Phaser Crystallographic Software</article-title><source>J Appl Crystallogr</source><year>2007</year><volume>40</volume><issue>Pt 4</issue><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="pmcid">PMC2483472</pub-id><pub-id pub-id-type="pmid">19461840</pub-id><pub-id pub-id-type="doi">10.1107/S0021889807021206</pub-id></element-citation></ref><ref id="R45"><label>(45)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>PD</given-names></name><name><surname>Afonine</surname><given-names>PV</given-names></name><name><surname>Bunkóczi</surname><given-names>G</given-names></name><name><surname>Chen</surname><given-names>VB</given-names></name><name><surname>Davis</surname><given-names>IW</given-names></name><name><surname>Echols</surname><given-names>N</given-names></name><name><surname>Headd</surname><given-names>JJ</given-names></name><name><surname>Hung</surname><given-names>L-W</given-names></name><name><surname>Kapral</surname><given-names>GJ</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>RW</given-names></name><name><surname>McCoy</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>PHENIX: A Comprehensive Python-Based System for Macromolecular Structure Solution</article-title><source>Acta Cryst D</source><year>2010</year><volume>66</volume><issue>2</issue><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmcid">PMC2815670</pub-id><pub-id pub-id-type="pmid">20124702</pub-id><pub-id pub-id-type="doi">10.1107/S0907444909052925</pub-id></element-citation></ref><ref id="R46"><label>(46)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P</given-names></name><name><surname>Lohkamp</surname><given-names>B</given-names></name><name><surname>Scott</surname><given-names>WG</given-names></name><name><surname>Cowtan</surname><given-names>K</given-names></name></person-group><article-title>Features and Development of Coot</article-title><source>Acta Cryst D</source><year>2010</year><volume>66</volume><issue>4</issue><fpage>486</fpage><lpage>501</lpage><pub-id pub-id-type="pmcid">PMC2852313</pub-id><pub-id pub-id-type="pmid">20383002</pub-id><pub-id pub-id-type="doi">10.1107/S0907444910007493</pub-id></element-citation></ref><ref id="R47"><label>(47)</label><element-citation publication-type="web"><person-group person-group-type="author"><name><surname>Smart</surname><given-names>OS</given-names></name><name><surname>Sharff</surname><given-names>A</given-names></name><name><surname>Holstein</surname><given-names>J</given-names></name><name><surname>Womack</surname><given-names>TO</given-names></name><name><surname>Flensburg</surname><given-names>C</given-names></name><name><surname>Keller</surname><given-names>P</given-names></name><name><surname>Paciorek</surname><given-names>W</given-names></name><name><surname>Vonrhein</surname><given-names>C</given-names></name><name><surname>Bricogne</surname><given-names>G</given-names></name></person-group><source>Grade2 Version 150</source><year>2021</year><comment><ext-link ext-link-type="uri" xlink:href="https://grade.globalphasing.org/">https://grade.globalphasing.org/</ext-link></comment></element-citation></ref><ref id="R48"><label>(48)</label><element-citation publication-type="other"><source>The PyMOL Molecular Graphics System, Version 3.0</source><year>2010</year></element-citation></ref><ref id="R49"><label>(49)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Callaghan</surname><given-names>CH</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Kirby</surname><given-names>SM</given-names></name><name><surname>Shingler</surname><given-names>AH</given-names></name></person-group><article-title>Novel Method for Detection of β-Lactamases by Using a Chromogenic Cephalosporin Substrate</article-title><source>Antimicrobial Agents and Chemotherapy</source><year>1972</year><volume>1</volume><issue>4</issue><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="pmcid">PMC444209</pub-id><pub-id pub-id-type="pmid">4208895</pub-id><pub-id pub-id-type="doi">10.1128/aac.1.4.283</pub-id></element-citation></ref><ref id="R50"><label>(50)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vanquelef</surname><given-names>E</given-names></name><name><surname>Simon</surname><given-names>S</given-names></name><name><surname>Marquant</surname><given-names>G</given-names></name><name><surname>Garcia</surname><given-names>E</given-names></name><name><surname>Klimerak</surname><given-names>G</given-names></name><name><surname>Delepine</surname><given-names>JC</given-names></name><name><surname>Cieplak</surname><given-names>P</given-names></name><name><surname>Dupradeau</surname><given-names>F-YRED</given-names></name></person-group><article-title>Server: A Web Service for Deriving RESP and ESP Charges and Building Force Field Libraries for New Molecules and Molecular Fragments</article-title><source>Nucleic Acids Research</source><year>2011</year><volume>39</volume><issue>suppl_2</issue><fpage>W511</fpage><lpage>W517</lpage><pub-id pub-id-type="pmcid">PMC3125739</pub-id><pub-id pub-id-type="pmid">21609950</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkr288</pub-id></element-citation></ref><ref id="R51"><label>(51)</label><element-citation publication-type="other"><person-group person-group-type="author"><name><surname>Case</surname><given-names>DA</given-names></name><name><surname>Belfon</surname><given-names>K</given-names></name><name><surname>Ben-Shalom</surname><given-names>SR</given-names></name><name><surname>Brozell</surname><given-names>SR</given-names></name><name><surname>Cerutti</surname><given-names>DS</given-names></name><name><surname>Cheatham</surname><given-names>TE</given-names><suffix>III</suffix></name><name><surname>Cruzeiro</surname><given-names>VWD</given-names></name><name><surname>Darden</surname><given-names>TA</given-names></name><name><surname>Duke</surname><given-names>RE</given-names></name><name><surname>Giambasu</surname><given-names>G</given-names></name><name><surname>Gilson</surname><given-names>MK</given-names></name><etal/></person-group><source>AMBER 2020</source><year>2020</year></element-citation></ref><ref id="R52"><label>(52)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>WL</given-names></name><name><surname>Chandrasekhar</surname><given-names>J</given-names></name><name><surname>Madura</surname><given-names>JD</given-names></name><name><surname>Impey</surname><given-names>RW</given-names></name><name><surname>Klein</surname><given-names>ML</given-names></name></person-group><article-title>Comparison of Simple Potential Functions for Simulating Liquid Water</article-title><source>The Journal of Chemical Physics</source><year>1983</year><volume>79</volume><issue>2</issue><fpage>926</fpage><lpage>935</lpage><pub-id pub-id-type="doi">10.1063/1.445869</pub-id></element-citation></ref><ref id="R53"><label>(53)</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roe</surname><given-names>DR</given-names></name><name><surname>Cheatham</surname><given-names>TEI</given-names></name></person-group><article-title>PTRAJ and CPPTRAJ: Software for Processing and Analysis of Molecular Dynamics Trajectory Data</article-title><source>J Chem Theory Comput</source><year>2013</year><volume>9</volume><issue>7</issue><fpage>3084</fpage><lpage>3095</lpage><pub-id pub-id-type="pmid">26583988</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><title>β-Lactam antibiotics and DBO β-lactamase inhibitors.</title><p>Representative penicillin (benzylpenicillin), carbapenem (meropenem) and cephalosporin (ceftazidime) β-lactam antibiotics, with the β-lactam ring highlighted in red. DBO BLIs used in this work are shown on the right, with the additional 1-aminoethoxy group of nacubactam highlighted in blue. The core rings of avibactam and the β-lactams are numbered.</p></caption><graphic xlink:href="EMS199779-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><title>DBO inhibition and turnover by serine β-lactamases.</title><p>DBO compounds inhibit SBLs by forming a covalent link with the catalytic serine via a (1.) carbamoylation reaction, analogous to acylation by β-lactam substrates. This results in formation of a carbamoyl-enzyme complex which has three proposed mechanistic fates: (2.) decarbamoylation to reform the intact DBO species, (3.) direct hydrolysis of the carbamoyl-enzyme complex and (4.) indirect hydrolysis via desulphation of the DBO-derived covalent intermediate<sup><xref ref-type="bibr" rid="R12">12</xref>–<xref ref-type="bibr" rid="R16">16</xref></sup>.</p></caption><graphic xlink:href="EMS199779-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><title>Crystal structure of OXA-48 bound to nacubactam.</title><p>(A) Crystal structure of OXA-48 carbamoyl-enzyme complex with nacubactam. Different shades of cyan represent different chains in the homodimer, chloride ion at the dimer interface is shown as a green sphere. (B) Nacubactam-derived carbamoyl-enzyme complex, mesh shows F<sub><italic>o</italic></sub><italic>-</italic>F<sub><italic>c</italic></sub> electron density from refinement carried out in the absence of ligand, contoured at 3σ. (C) Close-up of the chain B active site (cyan), overlaid with a previously determined structure of OXA-48 bound to avibactam (PDB 4S2K<sup><xref ref-type="bibr" rid="R14">14</xref></sup>, grey). (D) Surface views of the deacylating water channel in DBO-bound OXA-48 complexes, water molecules and chloride ions are represented as red and green spheres, respectively. Leu158 χ<sub><italic>1</italic></sub> (N-Cα-Cβ-Cγ) and Val120 χ<sub><italic>1</italic></sub> (N-Cα-Cβ-Cγ1) rotamers are highlighted in brackets; dashed line shows distance between the dual-occupancy water molecule (W1) and Leu158 Cδ<italic>2</italic>.</p></caption><graphic xlink:href="EMS199779-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><title>RMSF analysis of MM MD simulations of OXA-48:DBO carbamoyl-enzyme complexes.</title><p>(A) Difference in residue RMSF (ΔRMSF) between simulations of DBO-bound OXA-48, averaged across both chains of the protein homodimer, plotted against enzyme primary sequence. More positive values indicate greater fluctuation in nacubactam-, compared to avibactam-bound, OXA-48. The OXA-48 Ω-(yellow, residues 144 - 163), β5 – β6 (green, residues 212 - 219) and β7 – α10 (pink, residues 240 - 247) loops are highlighted on the graph and OXA-48:nacubactam crystal structure. (B) Comparisons of ΔRMSF values, coloured according to scale below, between DBO-bound and uncomplexed OXA-48 simulations, mapped onto the crystal structures of OXA-48 bound to nacubactam and avibactam. Thicker and more red backbones indicate more positive ΔRMSF values.</p></caption><graphic xlink:href="EMS199779-f004"/></fig><fig id="F5" position="float"><label>Figure 5</label><caption><title>Nacubactam and avibactam inhibition of naturally occurring OXA-48 variants OXA-163 and OXA-405.</title><p>(A) and (B) Active site overlays of OXA-48 (turquoise), OXA-163 (yellow) and OXA-405 (pink) bound to (A) avibactam and (B) nacubactam. Residues are shown as sticks, hydrogen bonding interactions in OXA-48:DBO structures as dashed lines and chloride ions as green spheres. Residues are numbered according to OXA-48, Leu158 χ<sub>1</sub> rotamer form is shown in brackets. (C) and (D) ΔRMSF analysis of MM MD simulations of (C) OXA-163 and (D) OXA-405 complexes with nacubactam and avibactam, mapped onto crystal structures of the respective nacubactam complexes.</p></caption><graphic xlink:href="EMS199779-f005"/></fig><fig id="F6" position="float"><label>Figure 6</label><caption><title>Analysis of distances between Ser118 Oγ and DBO N6 atoms in simulations of DBO carbamoyl complexes of OXA-48-related enzymes.</title><p>(A) Proportion (%) of simulations where Ser118 (Oγ) and N6 of the DBO-derived carbamoyl-enzyme complex are within 3.5 Å of each other, for each OXA-48-like enzyme. Triangles represent chain A and circles chain B of individual DBO complexes. (B) Overlay of OXA-48 avibactam- (PDB 4S2K<sup><xref ref-type="bibr" rid="R14">14</xref></sup>, grey) and nacubactam-bound (turquoise) structures, with the Ser118:DBO distance represented by a pale green dashed line.</p></caption><graphic xlink:href="EMS199779-f006"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Inhibitory values (IC<sub>50</sub>) for nacubactam and avibactam against OXA-48-like β-lactamases.</title></caption><table frame="hsides" rules="cols"><thead><tr><th valign="middle" align="center" style="border-top: hidden"/><th valign="middle" align="center" colspan="2">IC<sub>50</sub> values (μM) by inhibitor</th><th valign="middle" align="center" style="border-top: hidden"/></tr><tr style="border-top: solid thin; border-bottom: solid thin"><th valign="middle" align="center">Enzyme</th><th valign="middle" align="center">Nacubactam</th><th valign="middle" align="center">Avibactam</th><th valign="middle" align="center">Fold difference</th></tr></thead><tbody><tr style="background-color: #F2F2F2"><td valign="middle" align="center">OXA-48</td><td valign="middle" align="center">19.91</td><td valign="middle" align="center">0.26</td><td valign="middle" align="center">76.6</td></tr><tr><td valign="middle" align="center">OXA-163</td><td valign="middle" align="center">1.23</td><td valign="middle" align="center">0.20</td><td valign="middle" align="center">6.2</td></tr><tr style="background-color: #F2F2F2"><td valign="middle" align="center">OXA-405</td><td valign="middle" align="center">10.60</td><td valign="middle" align="center">0.99</td><td valign="middle" align="center">10.7</td></tr></tbody></table></table-wrap></floats-group></article>